{"id":"https://openalex.org/W2599891007","doi":"https://doi.org/10.1200/jco.2012.30.15_suppl.tps7615","title":"ARCHER: Dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC)\u2014A randomized double-blind phase III study.","display_name":"ARCHER: Dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC)\u2014A randomized double-blind phase III study.","publication_year":2012,"publication_date":"2012-05-20","ids":{"openalex":"https://openalex.org/W2599891007","doi":"https://doi.org/10.1200/jco.2012.30.15_suppl.tps7615","mag":"2599891007"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2012.30.15_suppl.tps7615","doi":"https://doi.org/10.1200/jco.2012.30.15_suppl.tps7615","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2012.30.15_suppl.tps7615","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5077287358","display_name":"Michael Joseph Boyer","orcid":"https://orcid.org/0000-0002-0452-2987","observed_orcids":["https://orcid.org/0000-0002-0452-2987"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael J. Boyer","raw_affiliation_strings":["Sydney Cancer Centre, Camperdown, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sydney Cancer Centre, Camperdown, Australia","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048675362","display_name":"Pasi Antero Janne","orcid":"https://orcid.org/0000-0002-7821-4928","observed_orcids":["https://orcid.org/0000-0002-7821-4928"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pasi A. Janne","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066717752","display_name":"Tony S.K. Mok","orcid":"https://orcid.org/0000-0002-8251-0551","observed_orcids":["https://orcid.org/0000-0002-8251-0551"]},"institutions":[{"id":"https://openalex.org/I177725633","display_name":"Chinese University of Hong Kong","ror":"https://ror.org/00t33hh48","country_code":"HK","type":"education","lineage":["https://openalex.org/I177725633"]}],"countries":["HK"],"is_corresponding":false,"raw_author_name":"Tony Mok","raw_affiliation_strings":["The Chinese University of Hong Kong, State Key Laboratory of South China, Sha Tin, Hong Kong, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Chinese University of Hong Kong, State Key Laboratory of South China, Sha Tin, Hong Kong, China","institution_ids":["https://openalex.org/I177725633"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033519199","display_name":"Kenneth John O'Byrne","orcid":"https://orcid.org/0000-0002-6754-5633","observed_orcids":["https://orcid.org/0000-0002-6754-5633"]},"institutions":[{"id":"https://openalex.org/I4210154619","display_name":"St. James's Hospital","ror":"https://ror.org/04c6bry31","country_code":"IE","type":"healthcare","lineage":["https://openalex.org/I4210154619"]}],"countries":["IE"],"is_corresponding":false,"raw_author_name":"Kenneth John O'Byrne","raw_affiliation_strings":["St. James's Hospital, Dublin, Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"St. James's Hospital, Dublin, Ireland","institution_ids":["https://openalex.org/I4210154619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052765751","display_name":"Luis G Paz-Ares","orcid":"https://orcid.org/0000-0002-1947-3364","observed_orcids":["https://orcid.org/0000-0002-1947-3364"]},"institutions":[{"id":"https://openalex.org/I4210153139","display_name":"Hospital Universitario Virgen del Roc\u00edo","ror":"https://ror.org/04vfhnm78","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210153139"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Luis G. Paz-Ares","raw_affiliation_strings":["Hospital Universitario Virgen del Roc\u00edo, Seville, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Universitario Virgen del Roc\u00edo, Seville, Spain","institution_ids":["https://openalex.org/I4210153139"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088178599","display_name":"Suresh S. Ramalingam","orcid":"https://orcid.org/0000-0002-0757-3106","observed_orcids":["https://orcid.org/0000-0002-0757-3106"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]},{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Suresh S. Ramalingam","raw_affiliation_strings":["Winship Cancer Institute, Emory University, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Winship Cancer Institute, Emory University, Atlanta, GA","institution_ids":["https://openalex.org/I150468666","https://openalex.org/I4390039307"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104110162","display_name":"Jane Q. Liang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jane Q Liang","raw_affiliation_strings":["Pfizer Oncology, Groton, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Oncology, Groton, CT","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060809215","display_name":"Ian W. Taylor","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ian Taylor","raw_affiliation_strings":["Pfizer Oncology, Groton, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Oncology, Groton, CT","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046783546","display_name":"Alicyn Campbell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alicyn Campbell","raw_affiliation_strings":["Pfizer Oncology, Groton, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Oncology, Groton, CT","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113760062","display_name":"Joseph P. O'Connell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph P. O'Connell","raw_affiliation_strings":["Pfizer Oncology, Groton, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Oncology, Groton, CT","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025624246","display_name":"Stephen P. Letrent","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen P. Letrent","raw_affiliation_strings":["Pfizer Oncology, La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Oncology, La Jolla, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5064686973","display_name":"Vladan Antic","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210099786","display_name":"Pfizer (Switzerland)","ror":"https://ror.org/00z8x2k69","country_code":"CH","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4210099786"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Vladan Antic","raw_affiliation_strings":["Pfizer AG, Zurich, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer AG, Zurich, Switzerland","institution_ids":["https://openalex.org/I4210099786"]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":14,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"30","issue":"15_suppl","first_page":"TPS7615","last_page":"TPS7615"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dacomitinib","display_name":"dacomitinib","score":0.996999979019165},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.9909999966621399},{"id":"https://openalex.org/keywords/advanced-non-small-cell-lung-cancer","display_name":"advanced non-small cell lung cancer","score":0.9369999766349792},{"id":"https://openalex.org/keywords/her-tyrosine-kinase-inhibitors","display_name":"HER tyrosine kinase inhibitors","score":0.9110000133514404},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9869999885559082},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.6449999809265137},{"id":"https://openalex.org/keywords/egfr-inhibitors","display_name":"EGFR inhibitors","score":0.38600000739097595},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.3720000088214874},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.453000009059906},{"id":"https://openalex.org/keywords/health-related-quality-of-life","display_name":"health-related quality of life","score":0.8109999895095825},{"id":"https://openalex.org/keywords/treatment-related-adverse-events","display_name":"treatment-related adverse events","score":0.5899999737739563},{"id":"https://openalex.org/keywords/egfr-mutation-status","display_name":"EGFR mutation status","score":0.39500001072883606},{"id":"https://openalex.org/keywords/alk-rearrangement","display_name":"ALK rearrangement","score":0.5210000276565552},{"id":"https://openalex.org/keywords/braf-mutation","display_name":"BRAF mutation","score":0.4309999942779541}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8927931785583496},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7625939846038818},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.7330209016799927},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.68211829662323},{"id":"https://openalex.org/C2781187634","wikidata":"https://www.wikidata.org/wiki/Q20969980","display_name":"KRAS","level":4,"score":0.6776233911514282},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.616848349571228},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6160535216331482},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5734997391700745},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5038048624992371},{"id":"https://openalex.org/C2779177807","wikidata":"https://www.wikidata.org/wiki/Q3658562","display_name":"non-small cell lung cancer (NSCLC)","level":4,"score":0.4800078272819519},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.43709972500801086},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.41090378165245056},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.38804811239242554},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3505816161632538},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.3192768394947052},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.3138309717178345},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.11954057216644287},{"id":"https://openalex.org/C81729549","wikidata":"https://www.wikidata.org/wiki/Q4649475","display_name":"A549 cell","level":3,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2012.30.15_suppl.tps7615","doi":"https://doi.org/10.1200/jco.2012.30.15_suppl.tps7615","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2012.30.15_suppl.tps7615","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9763000011444092,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","score":0.5600000023841858,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1994763147","https://openalex.org/W2120992361","https://openalex.org/W2023597833","https://openalex.org/W2093327299","https://openalex.org/W2076668512","https://openalex.org/W2541392164","https://openalex.org/W2360123363","https://openalex.org/W2168841302","https://openalex.org/W2896649837","https://openalex.org/W2035762060"],"abstract_inverted_index":{"TPS7615":[0],"Background:":[1],"D":[2,48,90,118,174,247],"is":[3,201],"a":[4,29,102,191,265,271],"highly":[5],"selective":[6],"irreversible":[7],"small":[8],"molecule":[9],"inhibitor":[10],"of":[11,16,25,117,125,185,190,212,220,223,274,309],"all":[12,131,244,340],"catalytically":[13],"active":[14],"members":[15],"the":[17,58,79,115,307,312],"HER":[18,326],"(human":[19],"epidermal":[20],"growth":[21],"factor":[22],"receptor)":[23],"family":[24],"tyrosine":[26],"kinases.":[27],"In":[28],"randomized":[30,171],"phase":[31,99,105],"II":[32,100],"trial":[33,108],"in":[34,57,78,121,241,243,251,311,342],"patients":[35],"(pts)":[36],"who":[37],"had":[38],"received":[39],"1\u20132":[40],"prior":[41,157],"systemic":[42],"therapy":[43],"regimens":[44],"for":[45,89,166],"adv":[46,128,135],"NSCLC,":[47,136,150,257],"demonstrated":[49],"significantly":[50],"longer":[51],"progression-free":[52],"survival":[53],"(PFS)":[54],"vs.":[55,62,86,248],"E":[56,120,178],"overall":[59,206],"population":[60],"(12.4":[61],"8.3":[63,87],"weeks;":[64],"HR=0.66,":[65],"P=0.012),":[66],"with":[67,119,127,134,140,145,253,315],"benefit":[68],"consistent":[69],"across":[70],"several":[71],"clinical":[72,107],"and":[73,91,137,163,215,217,225,232,238,250,259,262,276,293,328],"molecular":[74,167],"subgroups.":[75],"Median":[76],"PFS":[77,242],"KRAS":[80,141,254,290,329],"wild-type":[81],"(WT)":[82],"subgroup":[83],"was":[84,111],"16.1":[85],"weeks":[88],"E,":[92,249],"respectively":[93],"(HR=0.55,":[94],"P=0.006).":[95],"Methods:":[96],"Based":[97],"on":[98],"data,":[101],"randomized,":[103],"double-blinded":[104],"III":[106],"(ARCHER;":[109],"NCT01360554)":[110],"designed":[112],"to":[113,172,235,323],"compare":[114],"efficacy":[116],"two":[122],"co-primary":[123],"populations":[124,314],"pts":[126,133,139,194,245,252,341],"NSCLC:":[129],"(a)":[130],"enrolled":[132],"(b)":[138],"WT":[142],"NSCLC.":[143],"Pts":[144],"locally":[146],"adv/metastatic":[147],"pathologically":[148],"confirmed":[149],"radiologically":[151],"measurable":[152],"disease,":[153],"1":[154],"or":[155,177],"2":[156],"chemotherapy":[158],"regimens,":[159],"ECOG":[160,288],"PS":[161],"0\u20132,":[162],"tissue":[164],"available":[165],"analysis":[168,282],"will":[169,286,304,320],"be":[170,321],"receive":[173],"45":[175],"mg":[176,180],"150":[179],"orally":[181],"once":[182],"daily.":[183],"As":[184],"Jan":[186],"31,":[187],"2012,":[188],"117":[189],"planned":[192],"800":[193],"have":[195],"been":[196],"enrolled.":[197],"The":[198,279,300],"primary":[199,281],"endpoint":[200],"PFS.":[202],"Secondary":[203],"endpoints":[204],"include":[205,287],"survival,":[207],"objective":[208],"response":[209],"rate,":[210],"duration":[211],"response,":[213],"safety":[214],"tolerability,":[216],"pt-reported":[218],"outcomes":[219],"health-related":[221],"quality":[222],"life":[224],"disease-/treatment-related":[226],"symptoms.":[227],"Study":[228],"design":[229],"provides":[230],"90%":[231],"80%":[233],"power":[234],"detect":[236],"\u226533%":[237],"\u226545%":[239],"improvement":[240],"receiving":[246],"W":[255],"T":[256],"respectively,":[258],"HR":[260],"\u22640.75":[261],"\u22640.69":[263],"using":[264],"1-sided":[266],"stratified":[267,283],"log-rank":[268,284],"test":[269,285],"at":[270],"significance":[272],"level":[273],"0.015":[275],"0.01,":[277],"respectively.":[278],"final":[280],"PS,":[289],"mutation":[291,295,330],"status":[292,296],"EGFR":[294],"as":[297,332,334],"stratification":[298],"factors.":[299],"sample":[301],"sizes":[302],"above":[303],"also":[305],"allow":[306],"assessment":[308],"OS":[310],"co\u2011primary":[313],"adequate":[316],"power.":[317],"Post-hoc":[318],"analyses":[319],"performed":[322],"explore":[324],"EGFR,":[325],"family,":[327],"status,":[331],"well":[333],"other":[335],"tumor-derived":[336],"biomarkers":[337],"collected":[338],"from":[339],"this":[343],"trial.":[344]},"counts_by_year":[{"year":2018,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":7},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-08T09:06:37.294493","created_date":"2025-10-10T00:00:00"}